<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63784</article-id><article-id pub-id-type="doi">10.7554/eLife.63784</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Asprosin neutralizing antibodies as a treatment for metabolic syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-210199"><name><surname>Mishra</surname><given-names>Ila</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210200"><name><surname>Duerrschmid</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210201"><name><surname>Ku</surname><given-names>Zhiqiang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232653"><name><surname>He</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210202"><name><surname>Xie</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210203"><name><surname>Silva</surname><given-names>Elizabeth Sabath</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210204"><name><surname>Hoffman</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210205"><name><surname>Xin</surname><given-names>Wei</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0987-0443</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210206"><name><surname>Zhang</surname><given-names>Ningyan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33115"><name><surname>Xu</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18611"><name><surname>An</surname><given-names>Zhiqiang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9309-2335</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-210207"><name><surname>Chopra</surname><given-names>Atul R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1304-3777</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Harrington Discovery Institute</institution>, <institution>Case Western Reserve University</institution>, <addr-line><named-content content-type="city">Cleveland</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Texas Therapeutics Institute</institution>, <institution>University of Texas Health Science Center at Houston</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Pediatrics</institution>, <institution>Baylor College of Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Pathology</institution>, <institution>Case Western Reserve University,</institution>, <addr-line><named-content content-type="city">Cleveland</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Texas Therapeutics Institute</institution>, <institution>Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Pediatrics</institution>, <institution>Baylor College of Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">University of Texas Health Science Center at Houston</institution>, <institution>Brown Foundation Institute of Molecular Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-155059"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Reviewing editor</role><aff><institution>Medical College of Georgia at Augusta University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>atul.chopra@case.edu</email> (AC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>04</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e63784</elocation-id><history><date date-type="received"><day>07</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Mishra et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Mishra et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63784-v1.pdf"/><abstract><p><bold>Background</bold>: Recently, we discovered a new glucogenic and centrally-acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and its genetic loss results in reduced appetite, leanness and blood glucose burden, leading to protection from MS.</p><p><bold>Methods</bold>: We generated three independent monoclonal antibodies (mAbs) that recognize unique asprosin epitopes and investigated their preclinical efficacy and tolerability in the treatment of MS.</p><p><bold>Results</bold>: Anti-asprosin mAbs from three distinct species lowered appetite and body weight, and reduced blood glucose in a dose-dependent and epitope-agnostic fashion in three independent MS mouse models, with an IC<sub>50</sub> of ~1.5 mg/kg. The mAbs displayed a half-life of over 3 days in vivo, with equilibrium dissociation-constants in picomolar to low nanomolar range.</p><p><bold>Conclusions</bold>: We demonstrate that anti-asprosin mAbs are dual-effect pharmacologic therapy that targets two key pillars of MS – over-nutrition and hyperglycemia. This evidence paves the way for further development towards an investigational new drug application and subsequent human trials for treatment of MS, a defining physical ailment of our time.</p><p><bold>Funding</bold>: DK118290 and DK125403 (R01; National Institute of Diabetes and Digestive and Kidney Diseases), DK102529 (K08; National Institute of Diabetes and Digestive and Kidney Diseases), Caroline Wiess Law Scholarship (Baylor College of Medicine, Harrington Investigatorship (Harrington Discovery Institute at University Hospitals, Cleveland); Chao Physician Scientists Award (Baylor College of Medicine); RP150551 and RP190561 (Cancer Prevention and Research Institute of Texas; CPRIT)</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP150551 and RP190561</award-id><principal-award-recipient><name><surname>Chopra</surname><given-names>Atul R</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>AU-0042-20030616 and I-1834</award-id><principal-award-recipient><name><surname>An</surname><given-names>Zhiqiang</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK102529,DK118290</award-id><principal-award-recipient><name><surname>Chopra</surname><given-names>Atul R</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Harrington Discovery Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Chopra</surname><given-names>Atul R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Atul R Chopra, A.R.C. is a cofounder and director of Vizigen, Inc..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#2018-0042) of the Case Western Reserve University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Case Western Reserve University.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data analyzed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-63784-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>